Opus Genetics chief scientific and development officer departs
Ashwath Jayagopal is leaving his post at Opus Genetics effective October 19, 2026, and will serve as a paid consultant for six months.
Opus Genetics, Inc. disclosed in an 8-K filing that Dr. Ashwath Jayagopal is leaving his position as the company's Chief Scientific and Development Officer, with the change taking effect on October 19, 2026.1
Alongside the departure, the company signed a separation and release agreement with Jayagopal that also includes a consulting agreement, under which he will provide transition services to Opus Genetics at the company's request over a six-month period.1 Under that arrangement, Jayagopal will be paid $250 per hour for his consulting work.1
The filing also addresses his equity holdings. Any stock options Jayagopal has already vested as of his separation date will stay exercisable for the duration of the consulting period.1
Opus Genetics noted that further details of the arrangement are not fully spelled out in the 8-K itself. The company said the summary of the letter agreement, including the attached consulting agreement, is not complete and that the full text will appear as an exhibit in its upcoming Annual Report on Form 10-K covering the fiscal year ending December 31, 2026.1
The filing was signed by Dr. George Magrath, the company's Chief Executive Officer, and dated October 21, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.